SATAVAPTAN MONOPHOSPHATE
Inappropriate ADH Syndrome
SanofiSmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Inappropriate ADH Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tolvaptan King's College Hospital NHS Trust | Phase 3 | BBB |
Empagliflozin University Hospital, Basel, Switzerland | Phase 4 | BB |
Lixivaptan CardioKine Inc. | Phase 3 | BB |
Satavaptan Sanofi | Phase 3 | B |
Urea Helbert Rondon Berrios, MD, MS | Phase 2 | CCC |
Same molecule, other indications
SATAVAPTAN MONOPHOSPHATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →